免疫检查点抑制剂在非小细胞肺癌特殊人群中的作用
本文综述免疫检查点抑制剂(CPI)在非小细胞肺癌(NSCLC)特殊人群中的应用。注册III期试验高度选择人群,老年、体弱、PS≥2、合并自身免疫病、器官移植或慢性病毒感染患者代表性不足。现有数据提示老年患者获益与年轻患者相似且毒性未增加,但免疫联合化疗的毒性需关注;PS 3-4不推荐CPI,PS 2慎用;实体器官移植患者面临移植物丢失和死亡风险,治疗决策应多学科讨论。
要点
- 老年患者CPI获益与年轻患者相似且毒性未增加,但数据多来自亚组分析。
- PS 3-4不推荐CPI,PS 2需谨慎考虑。
- 实体器官移植患者CPI有移植物丢失和死亡风险,需多学科讨论。
核心结论
- CPI在NSCLC特殊人群中证据有限,老年患者可能获益相似且毒性未增加,但PS 3-4不推荐、PS 2慎用,器官移植患者风险显著。
研究设计与样本
- 本文为综述,基于注册III期试验及现有数据总结CPI在NSCLC特殊人群中的应用。
主要发现
- 注册III期试验中患者中位年龄比临床实践年轻10岁,且排除PS≥2患者。
- 按年龄的疗效数据多来自把握度不足的亚组分析,无年龄特异性安全性数据发表。
- 现有数据提示老年患者与年轻患者相比获益相似且毒性未增加。
- 免疫联合化疗的毒性升高引起对特殊人群的额外担忧,需充分选择患者。
- 实体器官移植患者面临移植物丢失和死亡的显著风险。
关键数值与推荐
- CPI不推荐用于PS 3-4的NSCLC患者。
- PS 2的NSCLC患者应谨慎考虑CPI。
- 合并自身免疫病(AID)且疾病活动度极低、慢性病毒感染控制良好的特定患者,CPI可能安全。
临床怎么用
- 对老年和体弱NSCLC患者使用CPI需评估PS和合并症,PS 3-4不推荐。
- PS 2患者使用CPI应谨慎权衡获益与毒性。
- 合并AID、器官移植或慢性病毒感染的患者,治疗决策应多学科讨论。
局限性
- 注册III期试验高度选择人群,排除老年、体弱和PS≥2患者,结果外推受限。
- 年龄相关疗效数据多来自把握度不足的亚组分析。
- 缺乏年龄特异性安全性数据。
- AID、器官移植或慢性病毒感染患者的证据水平低且不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, non-small cell lung cancer (NSCLC) entered in a new era of anticancer treatments with the success of checkpoint inhibitors (CPIs). These are now part of daily practice from locally advanced to metastatic NSCLC. However, the registration phase III trials are highly selective and not fully representative of the patients seen in real-world clinical practice. This is particularly obvious for older and frail patients, which represent the majority of NSCLC cases worldwide. The median age of the patients enrolled in clinical trials is 10 years younger than what is seen in clinic and patients with performance status (PS) ≥2 were excluded from registration studies. No strong conclusions can be drawn from the available trials where older and frail patients have been excluded. The majority of data on efficacy according to age are derived from underpowered subgroup analysis and there are no age-specific safety data published. Current data suggest that older patients may derive a similar benefit with no increased toxicity when compared with younger patients. However, the recent development of immunotherapychemotherapy combinations and the potential higher incidence of toxicity, raise additional concerns for these populations where adequate patient selection is paramount. CPI is not recommended for patients with PS 3-4 and should be considered with caution for those with PS 2. The evidence for patients with pre-existing autoimmune disease (AID), organ transplant or chronic viral infections (such us viral hepatitis B and C or human immunodeficiency virus) is less clear and low level. Although CPI are potentially safe in selected patients with AID with minimal activity and well-controlled chronic viral infections, patients with solid organ transplant face a significant risk of graft loss and death. Therefore, a decision to treat these groups of patients should always be discussed at a multidisciplinary level.
引用
- Califano R, Gomes F, Ackermann CJ, et al. Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations? Eur J Cancer. 2019. PMID: 31830688. doi:10.1016/j.ejca.2019.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。